Biohaven Ltd. (NYSE:BHVN) Director Acquires $999,207.54 in Stock

Biohaven Ltd. (NYSE:BHVN) Director Gregory Bailey acquired 25,503 shares of Biohaven stock in a transaction that occurred on Wednesday, April 24th. The shares were purchased at an average price of $39.18 per share, with a total value of $999,207.54. Following the transaction, the director now owns 1,600,071 shares of the company’s stock, valued at approximately $62,690,781.78. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Gregory Bailey also recently made the following trade(s):

• On Monday, April 22nd, Gregory Bailey acquired 48,780 shares of Biohaven stock. The shares were purchased at an average price of $41.00 per share, with a total value of $1,999,980.00.

Biohaven Stock Down 0.5 %

NYSE BHVN opened at $38.54 on Friday. The firm has a market cap of $3.40 billion, a price-to-earnings ratio of -6.81 and a beta of 1.18. The business has a 50-day moving average price of $51.32 and a 200-day moving average price of $41.79. Biohaven Ltd. has a twelve month low of $12.35 and a twelve month high of $62.21.

Biohaven (NYSE:BHVN) last released its quarterly earnings data on Thursday, February 29th. The company reported ($1.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.41) by ($0.40). Research analysts expect that Biohaven Ltd. will post -5.85 EPS for the current fiscal year.

Hedge Funds Weigh In On Biohaven

A number of hedge funds have recently made changes to their positions in BHVN. FSC Wealth Advisors LLC boosted its stake in shares of Biohaven by 50.0% in the third quarter. FSC Wealth Advisors LLC now owns 15,000 shares of the company’s stock worth $390,000 after acquiring an additional 5,000 shares during the period. Raymond James & Associates boosted its stake in Biohaven by 104.3% during the third quarter. Raymond James & Associates now owns 27,545 shares of the company’s stock valued at $716,000 after buying an additional 14,065 shares during the last quarter. Weybosset Research & Management LLC boosted its stake in Biohaven by 19.7% during the third quarter. Weybosset Research & Management LLC now owns 12,140 shares of the company’s stock valued at $316,000 after buying an additional 2,000 shares during the last quarter. Strs Ohio boosted its stake in Biohaven by 99.2% during the third quarter. Strs Ohio now owns 24,100 shares of the company’s stock valued at $626,000 after buying an additional 12,000 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in Biohaven by 13.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 38,071 shares of the company’s stock valued at $990,000 after buying an additional 4,540 shares during the last quarter. Institutional investors own 88.78% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently commented on BHVN. HC Wainwright upped their price objective on Biohaven from $50.00 to $63.00 and gave the company a “buy” rating in a research report on Monday, March 4th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Biohaven in a research report on Thursday, April 18th. JPMorgan Chase & Co. upped their price target on Biohaven from $32.00 to $56.00 and gave the stock an “overweight” rating in a research report on Friday, February 23rd. TD Cowen upped their price target on Biohaven from $35.00 to $55.00 and gave the stock an “outperform” rating in a research report on Friday, March 1st. Finally, UBS Group upped their price target on Biohaven from $59.00 to $60.00 and gave the stock a “buy” rating in a research report on Tuesday. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, Biohaven has an average rating of “Buy” and an average price target of $52.13.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.